Emerson, 2021 - Google Patents
The Role, Function, and Generation of Eomeshi CD8+ T Cells in OX40 and CTLA-4 Targeted Cancer ImmunotherapyEmerson, 2021
View PDF- Document ID
- 4363924227860503829
- Author
- Emerson D
- Publication year
External Links
Snippet
Monoclonal antibodies targeting key receptors that inhibit T cell function such as CTLA-4 and PD-1 have demonstrated the potency of checkpoint blockade, highlighted by long-term complete responses for metastatic cancers once thought incurable. However, only a subset …
- 229940045513 CTLA4 antagonist 0 title abstract description 156
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7109789B2 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
| US10098951B2 (en) | Antibody/T-cell receptor chimeric constructs and uses thereof | |
| JP2023052446A (en) | Compositions and methods for reprogramming T-cell receptors using fusion proteins | |
| JP2018515123A (en) | Compositions and methods for reprogramming TCRs using fusion proteins | |
| AU2018243664A1 (en) | Methods of treating T cell exhaustion by inhibiting or modulating T cell receptor signaling | |
| US20250152717A1 (en) | Binding proteins and engineered cells specific for neoantigens and uses thereof | |
| JP2021512637A (en) | Cyclin A1-specific T cell receptor and its use | |
| US20250011425A1 (en) | Compositions and methods for improved t cells | |
| WO2020198033A1 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| EP4321533A1 (en) | Cellular immunotherapy use | |
| Emerson | The Role, Function, and Generation of Eomeshi CD8+ T Cells in OX40 and CTLA-4 Targeted Cancer Immunotherapy | |
| JP2023526416A (en) | T cell receptor with VGLL1 specificity and methods of use thereof | |
| US20250213687A1 (en) | Therapeutic t cell product | |
| US20250235478A1 (en) | Chimeric antigen receptor modified regulatory t cells for treating cancer | |
| CA3043356A1 (en) | Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy | |
| Donini | Preclinical exploration of a novel cellular immunotherapy with CAR-redirected cytokine-induced killer lymphocytes (CIK) against soft tissue sarcomas | |
| WO2023235479A1 (en) | Compositions and methods for treating cancer | |
| Valia | Emerging Natural Killer Cell Immunotherapy for Acute Myeloid Leukemia | |
| AL-SULAITI | GENERATION AND CHARACTERIZATION OF" OFF-THE-SHELF" CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (CAR-T) TO TARGET CANCER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | |
| CA3234326A1 (en) | Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof | |
| TW202222841A (en) | Compositions and methods for treating mage-a1-expressing disease | |
| Moon | Engineering homing properties of cancer-specific T lymphocytes in adoption cell therapy | |
| JP2024527963A (en) | Universal Receptor Immune Cell Therapy | |
| WO2023060231A1 (en) | Compositions and methods for treating cancer using tcr fusion proteins in a combination therapy | |
| JP2025516627A (en) | Binding proteins specific for RAS neoantigens and uses thereof |